A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2013
At a glance
- Drugs ASG 5ME (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 07 May 2013 Status changed from recruiting to active, no longer recruiting, according to a Seattle Genetics media release.
- 09 Sep 2012 New source identified and integrated (Barbara Ann Karmanos Cancer Institute; 2010-073).